Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions

Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions
Author :
Publisher : DIANE Publishing
Total Pages : 16
Release :
ISBN-10 : 9781437985535
ISBN-13 : 143798553X
Rating : 4/5 (35 Downloads)

Book Synopsis Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions by :

Download or read book Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions written by and published by DIANE Publishing. This book was released on 2010 with total page 16 pages. Available in PDF, EPUB and Kindle. Book excerpt:


Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions Related Books

Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions
Language: en
Pages: 16
Authors:
Categories: Drugs
Type: BOOK - Published: 2010 - Publisher: DIANE Publishing

DOWNLOAD EBOOK

Delay, Deny, Defend
Language: en
Pages: 241
Authors: Jay M. Feinman
Categories: Business & Economics
Type: BOOK - Published: 2010-03-18 - Publisher: Penguin

DOWNLOAD EBOOK

An expose of insurance injustice and a plan for consumers and lawmakers to fight it Over the last two decades, insurance has become less of a safety net and mor
Generic Drugs
Language: en
Pages: 0
Authors: Christina M. Curtin
Categories: Drugs
Type: BOOK - Published: 2011 - Publisher: Nova Science Publishers

DOWNLOAD EBOOK

Brand-name pharmaceutical companies can delay generic competition that lowers prices by agreeing to pay a generic competitor to hold its competing product off t
Pay to Delay
Language: en
Pages: 184
Authors: United States. Congress. House. Committee on the Judiciary. Subcommittee on Courts and Competition Policy
Categories: Business & Economics
Type: BOOK - Published: 2010 - Publisher:

DOWNLOAD EBOOK

Competition Law and Policy in the Japanese Pharmaceutical Sector
Language: en
Pages: 252
Authors: Akira Negishi
Categories: Law
Type: BOOK - Published: 2022-02-08 - Publisher: Springer Nature

DOWNLOAD EBOOK

This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by